Oslo, Norway, February 2004 â Nutri Pharmaâs patented soy composition AbacorÂ® has been included in the newly launched Burgen âCholessterolâ bread from Allied Bakeries, one of three Burgen products which will hit UK supermarket shelves over the next few weeks. Burgen âCholessterolâ is being marketed as the ânatural choiceâ way to help lower cholesterol and maintain a healthy heart.
The AbacorÂ® blend of soy protein, fibre and phospholipids was chosen by Allied Bakeries because of its ability to provide the health benefits of cholesterol reduction far more effectively than the simple inclusion of soy protein alone. In fact, by direct comparison with the best commercially available soy protein, AbacorÂ® has been proven to be more than twice as effective at lowering cholesterol.
The launch is the culmination of several years of development activity between Nutri Pharma and Allied Bakeries, solving the problems associated with delivering a high level of AbacorÂ®, whilst maintaining the structure and flavour of a premium sliced loaf.
Nutri Pharma's unique scientific and intellectual property places the company in a leadership position within the growing field of specialty soy ingredients and functional food. Since the US Food and Drug Administration (FDA) in the United States approved a health claim relating soy to cholesterol reduction in 1999, the US soy market has seen double digit growth and, with the Joint Health Claims Initiative (JHCI) approved claim in the UK in 2002, significant market growth is now being experienced in this market.
With Nutri Pharmaâs superior, well-documented and patented products and technologies, the company is ideally positioned to partner with companies looking to take a lead in the growing functional foods market.
For further information on Nutri Pharma and its patented soy technology please visit www.nutripharma.com
- Ends -